Member Info for dactions

Jamrock - you must have a lot of money spare - keep encouraging people to use the opportunity to average down. Most don't have those sort of funds and look we're even below where this BoD bought in 2020 at 1.5p before all the hard work they did and then raking in the Covid profits. So, what's it all for ? Just for them to look after themselves ? You agree with everyone but apparently keep adding. Ace comes up with questions for the Meet and was one of the few to actually get them asked - but it was the answers or non-answers that she gave that are the problem and why the share is suffering. It's not as you said "sentiment is bad".

By the way in respect to one of the points you've made several times, I don't see any chance of the Bod buying back shares - if they were to do that I'd say that they've run out of ideas how to grow the business. It's very much a shame that they've seem to have lost the push/urgency to really expand this business for the benefit of all of us.

I can see we're going to have to be patient even longer.

All I'm asking Jamrock and all I'm saying is that we need better news and regular updates - not just the required twice a year 3 to 4 months past the date - and keep to the timelines she herself indicated. These are the very things - and only these things that have caused the drop in shareprice. She can control that without question but she isn't and it is a managerial failing solely of hers.

I don't doubt she has positives but her answers today extracted very little information - that is why I added my disappointment comments at the end of today's shareholder meeting. If she doesn't get the message that more communication is necessary, then we have a long wait before the sp recovers. Remember the sp was under a penny this morning whereas most people's average is 2p plus if they've averaged down but more likely nearer 4p I would guess.

What do you think will happen when the 15 : 1 consolidation takes place on the current status of info - I'll be amazed if it doesn't start falling even more. For a company generating good profits, excessively so 2021 & 2022 the sp should be over 3p plus but it's not going to happen unless she gets a grip on communication.

Surprisingly Ace's questions were all raised at the end of a lightweight presentation which was full of hopes and expectations but very little of substance which will help the shareprice in the near-term.

I have no doubt the company is making progress but it is still on the back of Covid sales. The chairman added a comment that the current sp reflects just the cash in the bank never mind anything else.

My comments to the Board at the end of the presentation were:
"Very disappointed at the amazing absence of any real answers to shareholders questions. No explanation was given as to what was happening to the wellness products that are already supposedly on sale. Yet more products coming to the market apparently soon and yet we have no knowledge as to those already on sale. We were told there would be news in the 4th quarter 2022 and yet no explanation why that timeline was missed. Lack of news or keeping to timelines previously announced is what has driven the sp down - and is totally within the CEO's remit to sort. "

I consider the results disappointing but they were what I was expecting and probably as the market was too. Consolidation sometimes works against and generates further selling.

Reserve judgement until I hear what’s said at the end of day shareholders Meet - although I am pessimistic based on what we’ve seen so far.

It is indeed disappointing OneJagielka - the lack of news from the company on its alternative covid products is the sole problem. If we knew what was happening to sales, or even if there are no sales but we were given some knowledge on what the BoD are going to do about it, then I'm quite sure we wouldn't be seeing these lows.

Adding to my earlier report of today's webinar, we know it was recorded so it may be that will become available to us. During the 1st part, the 3 experts gave examples of some of their case histories and we learned that it isn't just older people with comorbidities but all 3 have seen a significant rise in younger males seeking help. Their ED, if it is such, can actually be more a loss of confidence that they will be able to perform with their partner. Each of the Profs. felt that Eroxon was a safe alternative to stimulate the younger person's confidence and could see a wide take-up from this sector of males. This answer led into a discussion that Eroxon will be bought by younger males seeking an even stronger sexual experience/performance. Prof. Ralph said "definitely - it will be used recreationally".

In the Q & A part, a number of questions centred around the fact that the drug element was found not to be needed and that it was simply Dermasys (ie. the carrier component) that did the work. Prof. Ralph said that he agreed that Eroxon's effects were discovered by accident but the clinical trials clearly showed that it worked and there are plenty of ground-breaking examples in medicine where products were discovered by accident.

Prof. Block said "we don't think of it (Eroxon) as a drug but a device (OTC) that works" "it will be the users that will confirm its usefulness. It's non-toxic, works quickly, a topical therapy. A 1st line therapy" . Mention was made of alternative topical treatments such as Vitaros cream but the panel agreed that users had experienced strong burning sensations whereas not with Eroxon which made it their 1st line therapy in future..

I raised a question why the delay in marketing this to the UK and other European countries. I received a direct answer on the webinar Chat from Ken James of Futura that sales will be commencing in the near future" He wouldn't be drawn as to exactly when but a few moments later during the panel discussion, Prof. Ralph said marketing to the UK is the next month or two.

I'm going to try and be patient because it seems clear to me that as word gets around and pricing stays keen/competitive, whilst it might not help everyone, the clinical trials and today's judgement from the experts means sales are going to be massive. I hope this helps LTHs. GLA

That was the message from Prof David Ralph and echoed by the other two panellists Prof Giraldi and Prof Block. 3 professors of Urology. Todays webinar was overwhelmingly positive and they have no doubt that Eroxon will be the 1st line of treatment for ED.

Moreover they had no doubts this will be used by men seeking better sexual performance.

I have to admit to surprise ndr50 that the close was so low on the trades shown unless there's a large one yet to show. Now we're actually selling Eroxon, this has to be good news for us sooner or later.

GLA

Sorry ndr50 - joke wasn’t meant at you.

Thanks kdonkey1000 - yes that was a typo by me. My imagination isn’t up to yours - never thought that stimgel might stand for stimulating gel. Perhaps I too, like ndr50, need to get out more ??

Do we know why the product is being marketed as Eroxon Simgel not simply Eroxon ?

* Having read through the webinar's agenda and given the professional stature of participants

I have today received my confirmation to attend next week's webinar as follows:

Details
The webinar will provide an overview of the clinical data and clinical implications of Eroxon® Stimgel and what this means for you and your patients.

Eroxon® Stimgel
- Available over-the-counter in pharmacies providing fast access to patients and reducing workload in General Practice and Pharmacy for patients that typically need to be referred to a prescriber.
- Clinically proven as effective in two phase 3 trials conducted in Europe and the USA.
- Non-invasive topical application with minimal side-effects and no known adverse drug interactions.
- Fast-acting with 60% of erections reported within 10 minutes.

Webinar agenda
- Presentation by Prof. David Ralph on the background and clinical data behind Eroxon® Stimgel.
- Faculty Q&A where Prof. Annamaria Giraldi, Prof. David Ralph and Prof. Gerald Brock will answer questions posed by general practitioner Dr. Michael Smith on the clinical implications of Eroxon® Stimgel.
- Audience Q&A where the webinar audience will have the opportunity to submit questions to the expert panel.

Faculty:
Chair - Dr. Michael Smith: General Practitioner
Expert panel :
Prof. David Ralph: Urology Professor, President of the Sexual Advice Association, ESGURS Chairman, and advisor to NICE
Prof. Gerald Brock: Urology Professor and President of the ISSM
Prof. Annamaria Giraldi: Professor of Clinical Sexology and Senior Consultant Psychiatrist at The Sexological Clinic. Past president of the ISSM

-----------------
Having read through the webinar's agenda and given of participants for the Q & A sessions, I would expect it to be a very lively and informative meeting. Eroxon clearly will have to be recognised as a substantial new entry to this major market. Irrespective of the FDA's dragging its feet, it's clear to me as a very LTH, this is really excellent news for us and I foresee a major reappraisal of Futura's shares coming once this webinar publicity hits the markets.

Great news indeed - good luck to all those that have stuck it out and stayed the course.
GLA

I'm a LTH but want to hear what's happening to the market in the UK. Do we have any ideas when Coopers will release it here ?

The RNS is well crafted in my opinion - I have always said on the boards that the BoD were wrong to delay commercialisation whilst waiting on the FDA to reach a decision. The FDA does seem to be dragging its feet here - as we know that FUM has provided them their required data.

But sales are now happening and we can expect good reviews based on the extensive past trials, not least the 1000 cohort trial of several years back. Plus we have respected ED specialist David Ralph extolling its virtues. Hold steady and this will move forward.

Could be any number of reasons why meeting put back - from people absence like Naheed Memon as a non-executive director of the Company - to big news of new enterprises being delayed especially if it relates to Pak! stan given the turmoil in that country at moment with next month's supposed elections. Lots of speculation about possible deals in Balochistan an area which got ravaged by last year's floods.

It would be quite something if our small enterprise minnow called CORO was beneficially involved somehow - certainly good for the sp.

"This absolutely will rally strongly"

I'd like to think so too Moneysponge.
As a LTH I feel the time is right for this to turn and today at end of trading, someone bought 2,500,000 shares @ 1.61p so we're not alone with our positive thinking.

Davey50 - nice summing up with where we are with Woodbois.

1st quarter figures should be good - we know the year started well. And with LO and Pelham out of the way, surely this should be good for us sooner or later.

Green bin them - it's pointless giving them airtime.

There's too much comment on this thread that's without any substance. The thread title itself is meaningless as there are no impressive buys. The BoD said we'd here in the 4th quarter the progress of the new tests ant here we are coming near to the end of this year's 1st quarter.

It's the BoD's responsibility to update shareholders regularly - but worse to fly a date that has now been missed by very many weeks. It's this lack of information that has killed the sp. In the absence of news, the market will always fear the worst. As a LTH from Concepta days, I too am feeling very concerned as to the lack of news.